Skip to main content

Healthy Participants

A Study to Compare the Pharmacokinetics of CSL312 Administered by Prefilled Syringe Assembled to Autoinjector to the Pharmacokinetics Administered by Prefilled Syringe Assembled to Needle Safety Device in Healthy Subjects
NCT05306275 | Phase 1 | Interventional

This is an open-label, parallel-group, phase 1, single center study to assess the relative bioavailability of CSL312 administered subcutaneously via a prefilled syringe assembled to an autoinjector compared to a prefilled syringe assembled to a needle safety device in healthy, adult subjects.

Trial Information
1 Sites
132 Participants
18 Years to 55 Years

If interested, contact for more information

Anaheim Clinical Trials, LLC
Anaheim, California, 92801, United States

Study Eligibility Criteria

  • Healthy Male or female 18 to 55 years of age
  • Body weight in the range of ≥ 50 kg and ≤ 100 kg, with a body mass index (BMI) of ≥ 18 kg/m2 and ≤ 30 kg/m2
  • Received any live viral or bacterial vaccinations within 8 weeks of Screening or is expected to receive any live virus or bacterial vaccinations during the study or up to 4 months after last administration of the investigational product.
  • Evidence of current active infection, including severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).
  • Blood pressure or pulse rate measurements outside the normal range for the subject's age

Additional Studies

Additional studies can be found at